Biomedical subjects

V D'Alessio

Publications and source records attributed to V D'Alessio.

9 recordsLinked to original sources

PubMed2003

Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT).

The Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT) method is based on intravenous, sequential administration of a biotinylated antibody, avidin/streptavidin and (90)Y-labelled biotin. The hybridoma clone producing the monoclonal antitenascin antibody BC4, previously used for clinical applications, was found not suitable for further development because of the production of an additional, nonfunctional light chain. In order to solve this problem, the new cST2146 hybridoma clone was generated. The monoclonal antibody ST2146, produced by this hybridoma, having the same specificity as BC4 but lacking the nonfunctional light chain, was characterised. ST2146 was found able to bind human tenascin at an epitope strictly related, if not identical, to the antigenic epitope of BC4. It showed, compared to BC4, higher affinity and immunoreactivity and similar selectivity by immunohistochemistry. Biodistribution studies of biotinylated ST2146 and three other monoclonal antitenascin antibodies showed for ST2146 the highest and more specific tumour localisation in HT29-grafted nude mice. On the overall, ST2146 appears to be a good alternative to BC4 for further clinical development of PAGRIT.

Animals↗

PubMed1991

[Active specific immunotherapy of cancer using anti-idiotypic monoclonal antibodies].

Innovative approaches to cancer treatment have been made possible today by genetic engineering and hybridoma technologies. In this paper, attention is focused on the use of anti-idiotypic monoclonal antibodies such as internal tumor-associated antigens. These MoAbs may be able to overcome the immunosuppression in cancer patients by stimulating "silent" clones, or by allowing T cell help to become active, thus enhancing the overall immune response which the nominal antigen is unable to do. Preliminary experiences of active specific immunotherapy with monoclonal antiidiotypic antibodies in cancer patients are reported.

Animals↗

PubMed1988

Urinary neopterin and immunological features in patients with Kaposi's sarcoma.

We studied neopterin excretion levels and immunological features of 20 patients affected by Kaposi's sarcoma (KS), compared to 30 normal controls. Eighteen patients had the classic form of Kaposi's sarcoma (CKS), while two patients were anti-human immunodeficiency virus (HIV) seropositive and affected by the epidemic form associated with the acquired immunodeficiency syndrome (AIDS). In CKS patients, a trend of an increase of neopterin levels with more advanced stages appeared from our data whereas a significant reduction in CD3+ and CD4+ lymphocytes subsets was observed already at early stages (P less than 0.01). CD8+ cells did not show significant variations. A significant increase in serum IgA immunoglobulins (P less than 0.05) was also observed. Comparative analysis of the two patients affected by AIDS/KS showed the profound deficit in T-cell immunity but also the prognostic value of neopterin monitoring. Furthermore these findings seem to confirm Kaposi's sarcoma as an 'opportunistic neoplasia' and indicate neopterin as a useful prognostic marker.

Aged↗

PubMed1988

Immunologic abnormalities in patients with chronic delta infection.

Data reported in this paper emphasize the existence of close relationships between hepatitis delta patients and subjects affected by other viral diseases, first of all AIDS and related conditions. Some immunologic abnormalities characterizing initial stages of HIV infection (reduced CD4/CD8 ratio, based on increased CD8+ cells; B-cell polyclonal activation with the presence of circulating immune complexes) were found, in fact, also in delta patients. No statistically significant difference was observed by comparing delta vs no delta subjects.

Adolescent↗

PubMed1974